The Micro-Immunotherapy Medicine 2LARTH® Reduces Inflammation and Symptoms of Rheumatoid Arthritis In Vivo

Abstract EN

Background.

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease, which can cause cartilage and bone damages as well as pain and disability.

In order to prevent disease progression, reduce pain, and major symptoms of RA, one good strategy consists in targeting proinflammatory cytokines that have the key role in the vicious circle of synovial inflammation and pain.

The micro-immunotherapy medicine (MIM) 2LARTH® targets cytokines involved in inflammation.

Aim.

The aim of the study is to evaluate the effect of the MIM compared to vehicle in an in vivo model of RA, induced in mice after immunization with articular bovine type II collagen.

Methods.

Vehicle and MIM were dissolved in pure water (1 capsule in 100 ml) and 100 µl was given by gavage daily for 14 days.

To evaluate the severity of arthritis, wrist and ankle thickness was determined, paw edema was measured, and a clinical score from 0 to 4 was established.

Furthermore, histological analysis was performed.

To evaluate systemic inflammation, circulating levels of IL-1β and TNF-α were measured by ELISA.

Results.

Ankle thickness was found to be significantly reduced in MIM-treated mice compared to vehicle-treated mice (P<0.05) and compared to untreated me (P<0.01).

Paw edema was reduced, as well as clinical score attributed to MIM-treated mice in comparison with vehicle-treated mice and untreated CIA mice (P<0.01).

In line with these results, histological analysis confirmed that MIM reduced inflammation and joint destruction in comparison to controls.

No significant changes were found in plasmatic IL-1β levels between CIA and controls, while the levels of TNF-α significantly increased in the CIA group, and were lowered in MIM-treated mice (P<0.05 vs.

vehicle and vs.

CIA).

Conclusion.

The results indicate that the tested medicine reduces inflammation, histological, and clinical signs of RA in a CIA model.